<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Archiving and Interchange DTD v2.3 20070202//EN" "archivearticle.dtd"><article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article" xml:lang="EN"><front><journal-meta><journal-id journal-id-type="nlm-ta">PLoS ONE</journal-id><journal-id journal-id-type="publisher-id">plos</journal-id><journal-id journal-id-type="pmc">plosone</journal-id><journal-title>PLoS ONE</journal-title><issn pub-type="epub">1932-6203</issn><publisher><publisher-name>Public Library of Science</publisher-name><publisher-loc>San Francisco, USA</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">09-PONE-RA-09111R1</article-id><article-id pub-id-type="doi">10.1371/journal.pone.0005394</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="Discipline"><subject>Genetics and Genomics/Complex Traits</subject><subject>Genetics and Genomics/Genetics of Disease</subject><subject>Mental Health/Sleep Disorders</subject></subj-group></article-categories><title-group><article-title>Polymorphism Located between <italic>CPT1B</italic> and <italic>CHKB</italic>, and <italic>HLA-DRB1&#x0002a;1501-DQB1&#x0002a;0602</italic> Haplotype Confer Susceptibility to CNS Hypersomnias (Essential Hypersomnia)</article-title><alt-title alt-title-type="running-head">Susceptibility in Hypersomnias</alt-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Miyagawa</surname><given-names>Taku</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="corresp" rid="cor1"><sup>&#x0002a;</sup></xref></contrib><contrib contrib-type="author"><name><surname>Honda</surname><given-names>Makoto</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff3"><sup>3</sup></xref></contrib><contrib contrib-type="author"><name><surname>Kawashima</surname><given-names>Minae</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="aff" rid="aff4"><sup>4</sup></xref></contrib><contrib contrib-type="author"><name><surname>Shimada</surname><given-names>Mihoko</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Tanaka</surname><given-names>Susumu</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib><contrib contrib-type="author"><name><surname>Honda</surname><given-names>Yutaka</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref></contrib><contrib contrib-type="author"><name><surname>Tokunaga</surname><given-names>Katsushi</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib></contrib-group><aff id="aff1"><label>1</label><addr-line>Department of Human Genetics, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan</addr-line></aff><aff id="aff2"><label>2</label><addr-line>The Sleep Disorders Research Project, Tokyo Institute of Psychiatry, Tokyo, Japan</addr-line></aff><aff id="aff3"><label>3</label><addr-line>Japan Somnology Center, Neuropsychiatric Research Institute, Tokyo, Japan</addr-line></aff><aff id="aff4"><label>4</label><addr-line>Center for Narcolepsy, Stanford University School of Medicine, Palo Alto, California, United States of America</addr-line></aff><contrib-group><contrib contrib-type="editor"><name><surname>Rubinsztein</surname><given-names>David C.</given-names></name><role>Editor</role><xref ref-type="aff" rid="edit1"/></contrib></contrib-group><aff id="edit1">University of Cambridge, United Kingdom</aff><author-notes><corresp id="cor1">&#x0002a; E-mail: <email>miyagawa-taku@umin.ac.jp</email></corresp><fn fn-type="con"><p>Conceived and designed the experiments: TM MH MK ST KT. Performed the experiments: TM MS. Analyzed the data: TM. Contributed reagents/materials/analysis tools: TM MH MK YH KT. Wrote the paper: TM MH KT.</p></fn></author-notes><pub-date pub-type="collection"><year>2009</year></pub-date><pub-date pub-type="epub"><day>30</day><month>4</month><year>2009</year></pub-date><volume>4</volume><issue>4</issue><elocation-id>e5394</elocation-id><history><date date-type="received"><day>19</day><month>2</month><year>2009</year></date><date date-type="accepted"><day>31</day><month>3</month><year>2009</year></date></history><copyright-statement>Miyagawa et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</copyright-statement><copyright-year>2009</copyright-year><abstract><sec><title>Background</title><p>SNP rs5770917 located between <italic>CPT1B</italic> and <italic>CHKB</italic>, and <italic>HLA-DRB1&#x0002a;1501-DQB1&#x0002a;0602</italic> haplotype were previously identified as susceptibility loci for narcolepsy with cataplexy. This study was conducted in order to investigate whether these genetic markers are associated with Japanese CNS hypersomnias (essential hypersomnia: EHS) other than narcolepsy with cataplexy.</p></sec><sec><title>Principal Findings</title><p>EHS was significantly associated with SNP rs5770917 (<italic>P<sub>allele</sub></italic>&#x0200a;&#x0003d;&#x0200a;3.6&#x000d7;10<sup>&#x02212;3</sup>; OR&#x0200a;&#x0003d;&#x0200a;1.56; 95&#x00025; c.i.: 1.12&#x02013;2.15) and <italic>HLA-DRB1&#x0002a;1501-DQB1&#x0002a;0602</italic> haplotype (<italic>P</italic><sub>positivity</sub>&#x0200a;&#x0003d;&#x0200a;9.2&#x000d7;10<sup>&#x02212;11</sup>; OR&#x0200a;&#x0003d;&#x0200a;3.97; 95&#x00025; c.i.: 2.55&#x02013;6.19). No interaction between the two markers (SNP rs5770917 and <italic>HLA-DRB1&#x0002a;1501</italic>-<italic>DQB1&#x0002a;0602</italic> haplotype) was observed in EHS.</p></sec><sec><title>Conclusion</title><p>CPT1B, CHKB and HLA are candidates for susceptibility to CNS hypersomnias (EHS), as well as narcolepsy with cataplexy.</p></sec></abstract><counts><page-count count="3"/></counts></article-meta></front><body><sec id="s1"><title>Introduction</title><p>We previously reported that SNP rs5770917 located between the carnitine palmitoyltransferase 1B (<italic>CPT1B</italic>) and choline kinase beta (<italic>CHKB</italic>) genes was associated with susceptibility to narcolepsy with cataplexy after performing a genome-wide association study in Japanese and Korean populations (<italic>P</italic>&#x0200a;&#x0003d;&#x0200a;1.4&#x000d7;10<sup>&#x02212;7</sup>; odds ratio&#x0200a;&#x0003d;&#x0200a;1.68) <xref ref-type="bibr" rid="pone.0005394-Miyagawa1">&#x0005b;1&#x0005d;</xref>. In addition, significantly lower levels of both <italic>CPT1B</italic> and <italic>CHKB</italic> mRNA expression were observed in heterozygotes (TC) with the risk allele, as compared to homozygotes (TT) with the major allele <xref ref-type="bibr" rid="pone.0005394-Miyagawa1">&#x0005b;1&#x0005d;</xref>. Moreover, it is noteworthy that all narcoleptic patients with cataplexy in Japan carry a human leukocyte antigen (<italic>HLA)-DRB1&#x0002a;1501-DQB1&#x0002a;0602</italic> haplotype <xref ref-type="bibr" rid="pone.0005394-Juji1">&#x0005b;2&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0005394-Mignot1">&#x0005b;3&#x0005d;</xref>. Similar findings have been confirmed in individuals of European and African decent for whom the association is with <italic>DQB1&#x0002a;0602</italic>. <xref ref-type="bibr" rid="pone.0005394-Mignot1">&#x0005b;3&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0005394-Langdon1">&#x0005b;4&#x0005d;</xref>.</p><p>Central nervous system (CNS) hypersomnias other than narcolepsy with cataplexy are also complex disorders. Both genetic and environmental factors may contribute to the development of CNS hypersomnias, as in the case of narcolepsy with cataplexy <xref ref-type="bibr" rid="pone.0005394-Anderson1">&#x0005b;5&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0005394-Mignot2">&#x0005b;6&#x0005d;</xref>. Identification of the genetic factors has been challenging because of the low prevalence and the difficulty of diagnosis <xref ref-type="bibr" rid="pone.0005394-Anderson1">&#x0005b;5&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0005394-Mignot2">&#x0005b;6&#x0005d;</xref>. Although several reports have confirmed the association between some CNS hypersomnias and HLA, HLA typing was performed at the low-resolution serological level, and the association showed marginally statistical significance (0.01&#x0003c;<italic>P</italic>&#x0003c;0.05) because the number of cases was small <xref ref-type="bibr" rid="pone.0005394-Mignot2">&#x0005b;6&#x0005d;</xref>&#x02013;<xref ref-type="bibr" rid="pone.0005394-Honda2">&#x0005b;9&#x0005d;</xref>. Thus, in this study, we extended previous association studies to essential hypersomnia (EHS), which is a group of other CNS hypersomnias similar to narcolepsy with cataplexy in the symptom of excessive daytime sleepiness. Our diagnostic criteria for EHS comprised three clinical items: 1) recurrent daytime sleep episodes that occur basically every day over a period of at least 6 months; 2) absence of cataplexy; 3) the condition does not meet the diagnostic criteria of any other disorder causing excessive daytime sleepiness, such as sleep-apnea syndrome <xref ref-type="bibr" rid="pone.0005394-Honda2">&#x0005b;9&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0005394-Komada1">&#x0005b;10&#x0005d;</xref>. EHS is heterogeneous and consists of several CNS hypersomnias from aborted form of narcolepsy with cataplexy, narcolepsy without cataplexy and a part of idiopathic hypersomnia without long sleep time if we employed International Classification of Sleep Disorders 2<sup>nd</sup> edition criteria (AASM 2005). Our diagnostic criteria for EHS are focused on the daytime clinical characteristics of CNS hypersomnias <xref ref-type="bibr" rid="pone.0005394-Honda2">&#x0005b;9&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0005394-Komada1">&#x0005b;10&#x0005d;</xref>. A case-control association study was conducted in order to examine whether SNP rs5770917 and <italic>HLA-DRB1&#x0002a;1501-DQB1&#x0002a;0602</italic> haplotype are associated with EHS.</p></sec><sec sec-type="methods" id="s2"><title>Methods</title><p>Cases of EHS (n&#x0200a;&#x0003d;&#x0200a;137) and Controls (n&#x0200a;&#x0003d;&#x0200a;569) were unrelated Japanese living in Tokyo or neighboring areas. Written informed consent was obtained from participants, and the study was approved by the local institutional review boards of all collaborative organizations. Our diagnostic criteria for EHS comprised three clinical items: 1) recurrent daytime sleep episodes that occur basically every day over a period of at least 6 months; 2) absence of cataplexy; 3) the condition does not meet the diagnostic criteria of any other disorder causing excessive daytime sleepiness, such as sleep-apnea syndrome <xref ref-type="bibr" rid="pone.0005394-Honda2">&#x0005b;9&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0005394-Komada1">&#x0005b;10&#x0005d;</xref>.</p><p>Genotyping for SNP rs5770917 in cases was performed using Taqman genotyping assays. For controls, we used the genotype data from the previous genome-wide association study for narcolepsy with cataplexy <xref ref-type="bibr" rid="pone.0005394-Miyagawa1">&#x0005b;1&#x0005d;</xref>. Genotyping for <italic>HLA-DRB1</italic> and <italic>HLA-DQB1</italic> in cases was performed by Luminex Multi-Analyte Profiling system (xMAP) with a WAKFlow HLA typing kit (Wakunaga, Hiroshima, Japan). Briefly, target DNA was amplified by polymerase chain reaction (PCR) with biotinylated primers. The PCR amplicon was then denatured and hybridized to complementary oligonucleotide probes immobilized on fluorescent coded microsphere beads. At the same time, biotinylated PCR products were labeled with phycoerythrin-conjugated streptavidin and immediately examined with Luminex 100 (Luminex, Austin, TX). We did not perform HLA-typing in controls, instead we utilized <italic>HLA-DRB1</italic> and <italic>HLA-DQB1</italic> frequency data obtained from Japanese Society for Histocompatibility and Immunogenetics databank (a total of 516 Japanese general population were genotyped) (<ext-link ext-link-type="uri" xlink:href="http://jshi.umin.ac.jp/mhc/mhc_vol06-10/v08nakajima_all.pdf">http://jshi.umin.ac.jp/mhc/mhc_vol06-10/v08nakajima_all.pdf</ext-link>).</p><p>The observed associations of SNP rs5770917 and <italic>HLA-DRB1&#x0002a;1501-DQB1&#x0002a;0602</italic> haplotype were assessed by comparing frequency differences between cases and controls using chi-squared test. Population attributable risk percentage (PAR) for the risk genotypes (SNP rs5770917 C/C and T/C) was evaluated using the following formula, PAR&#x0200a;&#x0003d;&#x0200a;&#x0005b;p(RR&#x02013;1)&#x0005d;/&#x0005b;p(RR&#x02013;1)&#x0002b;1&#x0005d;), where p is calculated based on genotype frequencies in healthy controls and RR indicates relative risk of the risk genotypes. Odds ratio (OR) of the risk genotypes is similar to RR because of the low prevalence of EHS and narcolepsy with cataplexy. Interactions between the two markers (SNP rs5770917 and <italic>HLA-DRB1&#x0002a;1501</italic>-<italic>DQB1&#x0002a;0602</italic> haplotype) were calculated based on the positivity of each risk allele in EHS using the correlation coefficient.</p></sec><sec id="s3"><title>Results</title><p>In order to investigate whether SNP rs5770917 is also a genetic risk marker for the development of EHS, the SNP was genotyped in 137 cases and 569 controls. We found a significant difference between cases and controls (<italic>P<sub>allele</sub></italic>&#x0200a;&#x0003d;&#x0200a;3.6&#x000d7;10<sup>&#x02212;3</sup>; OR&#x0200a;&#x0003d;&#x0200a;1.56; 95&#x00025; c.i.: 1.12&#x02013;2.15) (<xref ref-type="table" rid="pone-0005394-t001">Table 1</xref>). Significant deviation from Hardy-Weinberg equilibrium (HWE) was not observed in either cases or controls. To estimate the epidemiological significance of SNP rs5770917 for EHS development in the Japanese population, PAR was found to be 14.2&#x00025; in our Japanese samples (<xref ref-type="table" rid="pone-0005394-t002">Table 2</xref>).</p><table-wrap id="pone-0005394-t001" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0005394.t001</object-id><label>Table 1</label><caption><title>Frequency of SNP rs5770917 in Japanese cases and controls.</title></caption><graphic id="pone-0005394-t001-1" xlink:href="pone.0005394.t001"/><table frame="hsides" rules="groups" alternate-form-of="pone-0005394-t001-1"><colgroup span="1"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/></colgroup><thead><tr><td align="left" rowspan="1" colspan="1"/><td colspan="3" align="left" rowspan="1">SNP rs5770917</td><td align="left" rowspan="1" colspan="1">HWE <italic>P</italic></td><td align="left" rowspan="1" colspan="1">RAF</td><td align="left" rowspan="1" colspan="1">OR (95&#x00025; c.i.)</td><td align="left" rowspan="1" colspan="1"><italic>P<sub>allele</sub></italic></td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">CC (&#x00025;)</td><td align="left" rowspan="1" colspan="1">TC (&#x00025;)</td><td align="left" rowspan="1" colspan="1">TT (&#x00025;)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Case</td><td align="left" rowspan="1" colspan="1">8 (5.8&#x00025;)</td><td align="left" rowspan="1" colspan="1">46 (33.6&#x00025;)</td><td align="left" rowspan="1" colspan="1">83 (60.6&#x00025;)</td><td align="left" rowspan="1" colspan="1">0.631</td><td align="left" rowspan="1" colspan="1">22.6&#x00025;</td><td align="left" rowspan="1" colspan="1">1.56 (1.12&#x02013;2.15)</td><td align="left" rowspan="1" colspan="1">3.6&#x000d7;10<sup>&#x02212;3</sup></td></tr><tr><td align="left" rowspan="1" colspan="1">Control</td><td align="left" rowspan="1" colspan="1">13 (2.3&#x00025;)</td><td align="left" rowspan="1" colspan="1">154 (27.1&#x00025;)</td><td align="left" rowspan="1" colspan="1">402 (70.7&#x00025;)</td><td align="left" rowspan="1" colspan="1">0.697</td><td align="left" rowspan="1" colspan="1">15.8&#x00025;</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr></tbody></table><table-wrap-foot><fn id="nt101"><p><italic>P</italic><sub>allele</sub> was calculated by comparing allele frequency differences in SNP rs5770917 between cases and controls using chi-squared test (one-tailed test).</p></fn><fn id="nt102"><p>RAF, risk allele frequency (C allele); OR, odds ratio; 95&#x00025; c.i., confidence interval.</p></fn><fn id="nt103"><p>HWE <italic>P</italic> represents P value from chi-squared test for Hardy-Weinberg equilibrium.</p></fn></table-wrap-foot></table-wrap><table-wrap id="pone-0005394-t002" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0005394.t002</object-id><label>Table 2</label><caption><title>Population attributable risk in SNP rs5770917.</title></caption><graphic id="pone-0005394-t002-2" xlink:href="pone.0005394.t002"/><table frame="hsides" rules="groups" alternate-form-of="pone-0005394-t002-2"><colgroup span="1"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/></colgroup><thead><tr><td align="left" rowspan="1" colspan="1"/><td colspan="2" align="left" rowspan="1">SNP rs5770917</td><td align="left" rowspan="1" colspan="1">OR (95&#x00025; c.i.)</td><td align="left" rowspan="1" colspan="1">PAR</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">C&#x0002b; (&#x00025;)</td><td align="left" rowspan="1" colspan="1">C&#x02212; (&#x00025;)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">EHS</td><td align="left" rowspan="1" colspan="1">54 (39.4&#x00025;)</td><td align="left" rowspan="1" colspan="1">83 (60.6&#x00025;)</td><td align="left" rowspan="1" colspan="1">1.57(1.06&#x02013;2.31)</td><td align="left" rowspan="1" colspan="1">14.2&#x00025;</td></tr><tr><td align="left" rowspan="1" colspan="1">Narcolepsy with cataplexy</td><td align="left" rowspan="1" colspan="1">169 (44.4&#x00025;)</td><td align="left" rowspan="1" colspan="1">212 (55.6&#x00025;)</td><td align="left" rowspan="1" colspan="1">1.92(1.46&#x02013;2.52)</td><td align="left" rowspan="1" colspan="1">21.2&#x00025;</td></tr></tbody></table><table-wrap-foot><fn id="nt104"><p>EHS, essential hypersomnia; OR, odds ratio; 95&#x00025; c.i., confidence interval; PAR, population attributable risk.</p></fn></table-wrap-foot></table-wrap><p>We also conducted an association study for <italic>HLA-DRB1&#x0002a;1501</italic>-<italic>DQB1&#x0002a;0602</italic> haplotype. Cases carried a significantly higher frequency of <italic>HLA-DRB1&#x0002a;1501</italic>-<italic>DQB1&#x0002a;0602</italic> haplotype than the Japanese general population (<italic>P</italic><sub>positivity</sub>&#x0200a;&#x0003d;&#x0200a;9.2&#x000d7;10<sup>&#x02212;11</sup>; OR&#x0200a;&#x0003d;&#x0200a;3.97; 95&#x00025; c.i.: 2.55&#x02013;6.19) (<xref ref-type="table" rid="pone-0005394-t003">Table 3</xref>).</p><table-wrap id="pone-0005394-t003" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0005394.t003</object-id><label>Table 3</label><caption><title>Positivity for <italic>HLA-DRB1&#x0002a;1501-DQB1&#x0002a;0602</italic> haplotype.</title></caption><graphic id="pone-0005394-t003-3" xlink:href="pone.0005394.t003"/><table frame="hsides" rules="groups" alternate-form-of="pone-0005394-t003-3"><colgroup span="1"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/></colgroup><thead><tr><td align="left" rowspan="1" colspan="1"/><td colspan="2" align="left" rowspan="1"><italic>HLA-DRB1&#x0002a;1501-DQB1&#x0002a;0602</italic> haplotype</td><td align="left" rowspan="1" colspan="1">OR (95&#x00025; c.i.)</td><td align="left" rowspan="1" colspan="1"><italic>P</italic><sub>positivity</sub></td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">&#x0002b; (&#x00025;)</td><td align="left" rowspan="1" colspan="1">&#x02212; (&#x00025;)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Case</td><td align="left" rowspan="1" colspan="1">47 (34.3&#x00025;)</td><td align="left" rowspan="1" colspan="1">90 (65.7&#x00025;)</td><td align="left" rowspan="1" colspan="1">3.97 (2.55&#x02013;6.19)</td><td align="left" rowspan="1" colspan="1">9.2&#x000d7;10<sup>&#x02212;11</sup></td></tr><tr><td align="left" rowspan="1" colspan="1">Control</td><td align="left" rowspan="1" colspan="1">60 (11.6&#x00025;)</td><td align="left" rowspan="1" colspan="1">456 (88.4&#x00025;)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr></tbody></table><table-wrap-foot><fn id="nt105"><p><italic>P</italic><sub>positivity</sub> was calculated by comparing the differnce in positivity for <italic>HLA-DRB1&#x0002a;1501-DQB1&#x0002a;0602</italic> haplotype between cases and controls using chi-squared test (one-tailed test).</p></fn><fn id="nt106"><p>OR, odds ratio; 95&#x00025; c.i., confidence interval.</p></fn></table-wrap-foot></table-wrap><p>The interaction between these two markers (SNP rs5770917 and <italic>HLA-DRB1&#x0002a;1501</italic>-<italic>DQB1&#x0002a;0602</italic> haplotype) was then calculated in EHS. No significant interaction was found (<italic>P</italic>&#x0200a;&#x0003d;&#x0200a;0.20; <italic>r<sup>2</sup></italic>&#x0200a;&#x0003d;&#x0200a;0.01), thus suggesting that these markers independently affect susceptibility to EHS.</p></sec><sec id="s4"><title>Discussion</title><p>In the present study, SNP rs5770917, which was identified in our previous genome-wide association study of narcolepsy with cataplexy <xref ref-type="bibr" rid="pone.0005394-Miyagawa1">&#x0005b;1&#x0005d;</xref>, was also found to confer susceptibility to EHS, a group of other CNS hypersomnias similar to narcolepsy with cataplexy. Thus, the SNP is considered to be a common risk marker for CNS hypersomnias in general. Nevertheless, the OR for narcolepsy with cataplexy (1.92) was greater than that for EHS (1.57) (<xref ref-type="table" rid="pone-0005394-t002">Table 2</xref>). Moreover, PAR for narcolepsy with cataplexy (21.2&#x00025;) was higher than that for EHS (14.2&#x00025;) (<xref ref-type="table" rid="pone-0005394-t002">Table 2</xref>), because the risk allele frequency of the SNP in narcolepsy with cataplexy (25.2&#x00025;) was greater than that in EHS (22.6&#x00025;) (<xref ref-type="table" rid="pone-0005394-t001">Table 1</xref>) <xref ref-type="bibr" rid="pone.0005394-Miyagawa1">&#x0005b;1&#x0005d;</xref>.</p><p>CPT1B is the rate-controlling enzyme of long-chain fatty acid &#x003b2;-oxidation in muscle mitochondria. CPT1B catalyzes the transport of long-chain fatty acyl-CoAs from the cytoplasm into the mitochondria through the carnitine shuttle <xref ref-type="bibr" rid="pone.0005394-McGarry1">&#x0005b;11&#x0005d;</xref>. Several reports have indicated the role of fatty acid &#x003b2;-oxidation and carnitine system in sleep regulation. First, fasted juvenile visceral steatosis (<italic>jvs</italic><sup>&#x02212;/&#x02212;</sup>) mice with systemic carnitine deficiency exhibit a higher frequency of fragmented wakefulness and rapid eye movement (REM) sleep, and reduced locomotor activity <xref ref-type="bibr" rid="pone.0005394-Yoshida1">&#x0005b;12&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0005394-Kuwajima1">&#x0005b;13&#x0005d;</xref>. These phenotypes in fasted <italic>jvs</italic><sup>&#x02212;/&#x02212;</sup> mice are similar to those in mouse models of narcolepsy <xref ref-type="bibr" rid="pone.0005394-Chemelli1">&#x0005b;14&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0005394-Hara1">&#x0005b;15&#x0005d;</xref>. Moreover, fasted <italic>jvs<sup>&#x02212;/&#x02212;</sup></italic> mice are activated by modafinil, which is used for the treatment of human narcolepsy <xref ref-type="bibr" rid="pone.0005394-Yoshida1">&#x0005b;12&#x0005d;</xref>. Second, mice deficient in short-chain acyl-CoA dehydrogenase (encoded by Acads), an enzyme catalyzing the first step of &#x003b2;-oxidation, have shown significantly slower theta frequency during REM sleep <xref ref-type="bibr" rid="pone.0005394-Tafti1">&#x0005b;16&#x0005d;</xref>. Administration of acetyl-L-carnitine, which is known to restore &#x003b2;-oxidation in the mitochondria, significantly recovers slow theta frequency in mutant mice <xref ref-type="bibr" rid="pone.0005394-Tafti1">&#x0005b;16&#x0005d;</xref>.</p><p>CHKB catalyzes the first phosphorylation reaction in the CDP-choline pathway for phosphatidylcholine synthesis <xref ref-type="bibr" rid="pone.0005394-Aoyama1">&#x0005b;17&#x0005d;</xref>. Phosphatidylcholine is the major membrane phospholipid in mammalian cells <xref ref-type="bibr" rid="pone.0005394-Kent1">&#x0005b;18&#x0005d;</xref> and inhibition of phosphatidylcholine synthesis triggers apoptosis in the brain <xref ref-type="bibr" rid="pone.0005394-Zweigner1">&#x0005b;19&#x0005d;</xref>. CDP-choline, which is used in the treatment of disorders of a cerebrovascular nature <xref ref-type="bibr" rid="pone.0005394-Fioravanti1">&#x0005b;20&#x0005d;</xref>, increases acetylcholine release <xref ref-type="bibr" rid="pone.0005394-Dixon1">&#x0005b;21&#x0005d;</xref>. Acetylcholine is a known REM- and wake-promoting neurotransmitter that increases narcolepsy symptoms <xref ref-type="bibr" rid="pone.0005394-Nishino1">&#x0005b;22&#x0005d;</xref>. Thus, either of these two genes (<italic>CPT1B</italic> and <italic>CHKB</italic>) is a plausible candidate for susceptibility to CNS hypersomnias (EHS), as well as narcolepsy with cataplexy.</p><p>To date, reports on the association between HLA and CNS hypersomnias other than narcolepsy with cataplexy have been based on serological typing and small sample size, thus yielding only marginal statistical significance <xref ref-type="bibr" rid="pone.0005394-Mignot2">&#x0005b;6&#x0005d;</xref>&#x02013;<xref ref-type="bibr" rid="pone.0005394-Honda2">&#x0005b;9&#x0005d;</xref>. In this study, we found a highly significant association between HLA and EHS using DNA-based high-resolution typing (<italic>P</italic><sub>positivity</sub>&#x0200a;&#x0003d;&#x0200a;9.2&#x000d7;10<sup>&#x02212;11</sup>), suggesting an immunological pathogenesis for EHS.</p><p>It is important to examine the interaction between SNP rs5770917 and HLA with regard to susceptibility to CNS hypersomnias. However, it is impossible to calculate the interaction between SNP rs5770917 and HLA in narcolepsy with cataplexy, because almost all patients possess <italic>HLA-DRB1&#x0002a;1501-DQB1&#x0002a;0602</italic> haplotype. No interaction was observed between SNP rs5770917 and <italic>HLA-DRB1&#x0002a;1501-DQB1&#x0002a;0602</italic> haplotype, suggesting that they are independent risk factors for not only EHS but also narcolepsy with cataplexy.</p><p>EHS analyzed in this study have recurrent daytime sleep episodes but do not have cataplexy. Thus, SNP rs5770917 located between <italic>CPT1B</italic> and <italic>CHKB</italic> might be involved in the pathogenesis of excessive daytime sleepiness, not cataplexy. Although our cases are heterogeneous, as exemplified by the findings that not all patients with EHS carry <italic>HLA-DRB1&#x0002a;1501-DQB1&#x0002a;0602</italic> haplotype, SNP rs5770917 is considered to be a common risk marker for both HLA positive and negative EHS, because no interaction was observed between SNP rs5770917 and <italic>HLA-DRB1&#x0002a;1501-DQB1&#x0002a;0602</italic> haplotype.</p><p>Our data suggest that EHS, a group of heterogeneous CNS hypersomnias similar to narcolepsy with cataplexy, might be in continuity with narcolepsy with cataplexy in common genetic background.</p></sec></body><back><ref-list><title>References</title><ref id="pone.0005394-Miyagawa1"><label>1</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Miyagawa</surname><given-names>T</given-names></name><name><surname>Kawashima</surname><given-names>M</given-names></name><name><surname>Nishida</surname><given-names>N</given-names></name><name><surname>Ohashi</surname><given-names>J</given-names></name><name><surname>Kimura</surname><given-names>R</given-names></name><etal/></person-group><year>2008</year><article-title>Variant between CPT1B and CHKB associated with susceptibility to narcolepsy.</article-title><source>Nat Genet</source><volume>40</volume><fpage>1324</fpage><lpage>1328</lpage><pub-id pub-id-type="pmid">18820697</pub-id></citation></ref><ref id="pone.0005394-Juji1"><label>2</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Juji</surname><given-names>T</given-names></name><name><surname>Satake</surname><given-names>M</given-names></name><name><surname>Honda</surname><given-names>Y</given-names></name><name><surname>Doi</surname><given-names>Y</given-names></name></person-group><year>1984</year><article-title>HLA antigens in Japanese patients with narcolepsy. All the patients were DR2 positive.</article-title><source>Tissue Antigens</source><volume>24</volume><fpage>316</fpage><lpage>319</lpage><pub-id pub-id-type="pmid">6597978</pub-id></citation></ref><ref id="pone.0005394-Mignot1"><label>3</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Mignot</surname><given-names>E</given-names></name><name><surname>Lin</surname><given-names>L</given-names></name><name><surname>Rogers</surname><given-names>W</given-names></name><name><surname>Honda</surname><given-names>Y</given-names></name><name><surname>Qiu</surname><given-names>X</given-names></name><etal/></person-group><year>2001</year><article-title>Complex HLA-DR and -DQ interactions confer risk of narcolepsy-cataplexy in three ethnic groups.</article-title><source>Am J Hum Genet</source><volume>68</volume><fpage>686</fpage><lpage>699</lpage><pub-id pub-id-type="pmid">11179016</pub-id></citation></ref><ref id="pone.0005394-Langdon1"><label>4</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Langdon</surname><given-names>N</given-names></name><name><surname>Welsh</surname><given-names>KI</given-names></name><name><surname>van Dam</surname><given-names>M</given-names></name><name><surname>Vaughan</surname><given-names>RW</given-names></name><name><surname>Parkes</surname><given-names>D</given-names></name></person-group><year>1984</year><article-title>Genetic markers in narcolepsy.</article-title><source>Lancet</source><volume>2</volume><fpage>1178</fpage><lpage>1180</lpage><pub-id pub-id-type="pmid">6150235</pub-id></citation></ref><ref id="pone.0005394-Anderson1"><label>5</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Anderson</surname><given-names>KN</given-names></name><name><surname>Pilsworth</surname><given-names>S</given-names></name><name><surname>Sharples</surname><given-names>LD</given-names></name><name><surname>Smith</surname><given-names>IE</given-names></name><name><surname>Shneerson</surname><given-names>JM</given-names></name></person-group><year>2007</year><article-title>Idiopathic hypersomnia: a study of 77 cases.</article-title><source>Sleep</source><volume>30</volume><fpage>1274</fpage><lpage>1281</lpage><pub-id pub-id-type="pmid">17969461</pub-id></citation></ref><ref id="pone.0005394-Mignot2"><label>6</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Mignot</surname><given-names>E</given-names></name><name><surname>Lammers</surname><given-names>GJ</given-names></name><name><surname>Ripley</surname><given-names>B</given-names></name><name><surname>Okun</surname><given-names>M</given-names></name><name><surname>Nevsimalova</surname><given-names>S</given-names></name><etal/></person-group><year>2002</year><article-title>The role of cerebrospinal fluid hypocretin measurement in the diagnosis of narcolepsy and other hypersomnias.</article-title><source>Arch Neurol</source><volume>59</volume><fpage>1553</fpage><lpage>1562</lpage><pub-id pub-id-type="pmid">12374492</pub-id></citation></ref><ref id="pone.0005394-Hong1"><label>7</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hong</surname><given-names>SC</given-names></name><name><surname>Lin</surname><given-names>L</given-names></name><name><surname>Jeong</surname><given-names>JH</given-names></name><name><surname>Shin</surname><given-names>YK</given-names></name><name><surname>Han</surname><given-names>JH</given-names></name><etal/></person-group><year>2006</year><article-title>A study of the diagnostic utility of HLA typing, CSF hypocretin-1 measurements, and MSLT testing for the diagnosis of narcolepsy in 163 Korean patients with unexplained excessive daytime sleepiness.</article-title><source>Sleep</source><volume>29</volume><fpage>1429</fpage><lpage>1438</lpage><pub-id pub-id-type="pmid">17162989</pub-id></citation></ref><ref id="pone.0005394-Honda1"><label>8</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Honda</surname><given-names>Y</given-names></name><name><surname>Juji</surname><given-names>T</given-names></name><name><surname>Matsuki</surname><given-names>K</given-names></name><name><surname>Naohara</surname><given-names>T</given-names></name><name><surname>Satake</surname><given-names>M</given-names></name><etal/></person-group><year>1986</year><article-title>HLA-DR2 and Dw2 in narcolepsy and in other disorders of excessive somnolence without cataplexy.</article-title><source>Sleep</source><volume>9</volume><fpage>133</fpage><lpage>142</lpage><pub-id pub-id-type="pmid">3010426</pub-id></citation></ref><ref id="pone.0005394-Honda2"><label>9</label><citation citation-type="book"><person-group person-group-type="author"><name><surname>Honda</surname><given-names>Y</given-names></name><name><surname>Takahashi</surname><given-names>Y</given-names></name><name><surname>Honda</surname><given-names>M</given-names></name><name><surname>Watanabe</surname><given-names>Y</given-names></name><name><surname>Sato</surname><given-names>T</given-names></name><etal/></person-group><year>1998</year><source>Genetic aspects of narcolepsy</source><publisher-name>Sleep and Sleep Disorders: From Molecule to Behavior; Hayaishi O and Inoue S. Academic Press</publisher-name><fpage>341</fpage><lpage>358</lpage></citation></ref><ref id="pone.0005394-Komada1"><label>10</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Komada</surname><given-names>Y</given-names></name><name><surname>Inoue</surname><given-names>Y</given-names></name><name><surname>Mukai</surname><given-names>J</given-names></name><name><surname>Shirakawa</surname><given-names>S</given-names></name><name><surname>Takahashi</surname><given-names>K</given-names></name><etal/></person-group><year>2005</year><article-title>Difference in the characteristics of subjective and objective sleepiness between narcolepsy and essential hypersomnia.</article-title><source>Psychiatry Clin Neurosci</source><volume>59</volume><fpage>194</fpage><lpage>199</lpage><pub-id pub-id-type="pmid">15823167</pub-id></citation></ref><ref id="pone.0005394-McGarry1"><label>11</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>McGarry</surname><given-names>JD</given-names></name><name><surname>Brown</surname><given-names>NF</given-names></name></person-group><year>1997</year><article-title>The mitochondrial carnitine palmitoyltransferase system. From concept to molecular analysis.</article-title><source>Eur J Biochem</source><volume>244</volume><fpage>1</fpage><lpage>14</lpage><pub-id pub-id-type="pmid">9063439</pub-id></citation></ref><ref id="pone.0005394-Yoshida1"><label>12</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Yoshida</surname><given-names>G</given-names></name><name><surname>Li</surname><given-names>MX</given-names></name><name><surname>Horiuchi</surname><given-names>M</given-names></name><name><surname>Nakagawa</surname><given-names>S</given-names></name><name><surname>Sakata</surname><given-names>M</given-names></name><etal/></person-group><year>2006</year><article-title>Fasting-induced reduction in locomotor activity and reduced response of orexin neurons in carnitine-deficient mice.</article-title><source>Neurosci Res</source><volume>55</volume><fpage>78</fpage><lpage>86</lpage><pub-id pub-id-type="pmid">16540195</pub-id></citation></ref><ref id="pone.0005394-Kuwajima1"><label>13</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kuwajima</surname><given-names>M</given-names></name><name><surname>Fujihara</surname><given-names>H</given-names></name><name><surname>Sei</surname><given-names>H</given-names></name><name><surname>Umehara</surname><given-names>A</given-names></name><name><surname>Sei</surname><given-names>M</given-names></name><etal/></person-group><year>2007</year><article-title>Reduced Carnitine Level Causes Death from Hypoglycemia: Possible Involvement of Suppression of Hypothalamic Orexin Expression During Weaning Period.</article-title><source>Endocr J</source></citation></ref><ref id="pone.0005394-Chemelli1"><label>14</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Chemelli</surname><given-names>RM</given-names></name><name><surname>Willie</surname><given-names>JT</given-names></name><name><surname>Sinton</surname><given-names>CM</given-names></name><name><surname>Elmquist</surname><given-names>JK</given-names></name><name><surname>Scammell</surname><given-names>T</given-names></name><etal/></person-group><year>1999</year><article-title>Narcolepsy in orexin knockout mice: molecular genetics of sleep regulation.</article-title><source>Cell</source><volume>98</volume><fpage>437</fpage><lpage>451</lpage><pub-id pub-id-type="pmid">10481909</pub-id></citation></ref><ref id="pone.0005394-Hara1"><label>15</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hara</surname><given-names>J</given-names></name><name><surname>Beuckmann</surname><given-names>CT</given-names></name><name><surname>Nambu</surname><given-names>T</given-names></name><name><surname>Willie</surname><given-names>JT</given-names></name><name><surname>Chemelli</surname><given-names>RM</given-names></name><etal/></person-group><year>2001</year><article-title>Genetic ablation of orexin neurons in mice results in narcolepsy, hypophagia, and obesity.</article-title><source>Neuron</source><volume>30</volume><fpage>345</fpage><lpage>354</lpage><pub-id pub-id-type="pmid">11394998</pub-id></citation></ref><ref id="pone.0005394-Tafti1"><label>16</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Tafti</surname><given-names>M</given-names></name><name><surname>Petit</surname><given-names>B</given-names></name><name><surname>Chollet</surname><given-names>D</given-names></name><name><surname>Neidhart</surname><given-names>E</given-names></name><name><surname>de Bilbao</surname><given-names>F</given-names></name><etal/></person-group><year>2003</year><article-title>Deficiency in short-chain fatty acid beta-oxidation affects theta oscillations during sleep.</article-title><source>Nat Genet</source><volume>34</volume><fpage>320</fpage><lpage>325</lpage><pub-id pub-id-type="pmid">12796782</pub-id></citation></ref><ref id="pone.0005394-Aoyama1"><label>17</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Aoyama</surname><given-names>C</given-names></name><name><surname>Liao</surname><given-names>H</given-names></name><name><surname>Ishidate</surname><given-names>K</given-names></name></person-group><year>2004</year><article-title>Structure and function of choline kinase isoforms in mammalian cells.</article-title><source>Prog Lipid Res</source><volume>43</volume><fpage>266</fpage><lpage>281</lpage><pub-id pub-id-type="pmid">15003397</pub-id></citation></ref><ref id="pone.0005394-Kent1"><label>18</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kent</surname><given-names>C</given-names></name></person-group><year>1997</year><article-title>CTP:phosphocholine cytidylyltransferase.</article-title><source>Biochim Biophys Acta</source><volume>1348</volume><fpage>79</fpage><lpage>90</lpage><pub-id pub-id-type="pmid">9370319</pub-id></citation></ref><ref id="pone.0005394-Zweigner1"><label>19</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Zweigner</surname><given-names>J</given-names></name><name><surname>Jackowski</surname><given-names>S</given-names></name><name><surname>Smith</surname><given-names>SH</given-names></name><name><surname>Van Der Merwe</surname><given-names>M</given-names></name><name><surname>Weber</surname><given-names>JR</given-names></name><etal/></person-group><year>2004</year><article-title>Bacterial inhibition of phosphatidylcholine synthesis triggers apoptosis in the brain.</article-title><source>J Exp Med</source><volume>200</volume><fpage>99</fpage><lpage>106</lpage><pub-id pub-id-type="pmid">15238609</pub-id></citation></ref><ref id="pone.0005394-Fioravanti1"><label>20</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Fioravanti</surname><given-names>M</given-names></name><name><surname>Yanagi</surname><given-names>M</given-names></name></person-group><year>2005</year><article-title>Cytidinediphosphocholine (CDP-choline) for cognitive and behavioural disturbances associated with chronic cerebral disorders in the elderly.</article-title><source>Cochrane Database Syst Rev</source><fpage>CD000269</fpage><pub-id pub-id-type="pmid">15846601</pub-id></citation></ref><ref id="pone.0005394-Dixon1"><label>21</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Dixon</surname><given-names>CE</given-names></name><name><surname>Ma</surname><given-names>X</given-names></name><name><surname>Marion</surname><given-names>DW</given-names></name></person-group><year>1997</year><article-title>Effects of CDP-choline treatment on neurobehavioral deficits after TBI and on hippocampal and neocortical acetylcholine release.</article-title><source>J Neurotrauma</source><volume>14</volume><fpage>161</fpage><lpage>169</lpage><pub-id pub-id-type="pmid">9104933</pub-id></citation></ref><ref id="pone.0005394-Nishino1"><label>22</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Nishino</surname><given-names>S</given-names></name><name><surname>Mignot</surname><given-names>E</given-names></name></person-group><year>1997</year><article-title>Pharmacological aspects of human and canine narcolepsy.</article-title><source>Prog Neurobiol</source><volume>52</volume><fpage>27</fpage><lpage>78</lpage><pub-id pub-id-type="pmid">9185233</pub-id></citation></ref></ref-list><fn-group><fn fn-type="conflict"><p><bold>Competing Interests: </bold>The authors have declared that no competing interests exist.</p></fn><fn fn-type="financial-disclosure"><p><bold>Funding: </bold>This study is supported by Grant-in-Aid for Scientific Research on Priority Areas &#x0201c;Comprehensive Genomics&#x0201d; and &#x0201c;Applied Genomics&#x0201d; from the Ministry of Education, Culture, Sports, Science and Technology of Japan, Grant-in-Aid for JSPS fellows and Astellas Foundation for Research on Metabolic Disorders. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.</p></fn></fn-group></back></article> 